Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

Por Ollivier, Julien, Carrié, Cédric, d’Houdain, Nicolas, Djabarouti, Sarah, Petit, Laurent, Xuereb, Fabien, Legeron, Rachel, Biais, Matthieu, Breilh, Dominique
Publicado no Antimicrob Agents Chemother (2019)

Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study

Por Djabarouti, Sarah, Breilh, Dominique, Duffau, Pierre, Lazaro, Estibaliz, Greib, Carine, Caubet, Olivier, Saux, Marie-Claude, Pellegrin, Jean-Luc, Viallard, Jean-François
Publicado em 2010

Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study

Por Djabarouti, Sarah, Breilh, Dominique, Duffau, Pierre, Lazaro, Estibaliz, Greib, Carine, Caubet, Olivier, Saux, Marie-Claude, Pellegrin, Jean-Luc, Viallard, Jean-François
Publicado em 2011

Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases

Por Streicher, Caroline, Djabarouti, Sarah, Xuereb, Fabien, Lazaro, Estibaliz, Legeron, Rachel, Bouchet, Stéphane, Greib, Carine, Breilh, Dominique, Pellegrin, Jean-Luc, Viallard, Jean-François
Publicado no Br J Clin Pharmacol (2014)